Making cold malignant pleural effusions hot: driving novel immunotherapies

Making cold malignant pleural effusions hot: driving novel immunotherapies

Malignant pleural effusions, arising from either primary mesotheliomas or secondary malignancies, heralds advanced disease and poor prognosis. Current treatments, including therapeutic thoracentesis and tube thoracostomy, are largely palliative. The immunosuppressive environment within the pleural c...

Full description

Bibliographic Details
Main Authors: Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
Format: Article
Language:English
Published: Taylor & Francis Group 2019-04-01
Series:OncoImmunology
Subjects:
malignant pleural effusion (mpe)
non-small cell lung cancer (nsclc)
mesothelioma (mm)
damage associated molecular pattern molecules (damps)
cancer immunotherapies
interleukin-2 (il-2)
adoptive cell therapy (act)
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1554969

Internet

http://dx.doi.org/10.1080/2162402X.2018.1554969

Similar Items